Latest Commercial Operations News

ABx Group’s mixed rare earth carbonate from Tasmania’s Deep Leads project has earned strong validation from US-based Rare Earth Technologies Inc, confirming its high purity and compatibility with cutting-edge separation technology.

Memphasys Limited confirms uninterrupted operations across the Middle East and North Africa, securing new orders and advancing regulatory approvals despite ongoing regional tensions.

TMK Energy has raised $6 million in a heavily oversubscribed placement led by coal seam gas experts, aiming to accelerate drilling and commercialisation at its Gurvantes XXXV project.

InteliCare Holdings has appointed seasoned healthcare executive Angus Cameron as CEO to lead its transition from pilot projects to full-scale commercial deployment following a major aged care contract.

Metallium Limited reports rapid progress at its Gator Point Technology Campus in Texas, advancing its proprietary Flash Joule Heating technology to recover critical metals from electronic waste. The company targets processing 8,000 tonnes of printed circuit boards annually by late 2026.

RLF AgTech has built a promising $3 million sales pipeline in Australia from scratch while securing $7.2 million in pre-paid orders in China, signalling robust growth ahead of the 2026 season.

Straker Ltd announces a pivotal leadership shift with the appointment of David Sowerby and Indiver Nagpal as Co-CEOs, marking a new era focused on commercial expansion and AI innovation. Founder Grant Straker transitions to a strategic board role to steer the company’s AI future.

Metal Powder Works Limited reported a substantial increase in its half-year loss to $3.7 million, driven by investments in production scaling and market expansion. Revenue more than doubled, reflecting strong demand in defence, aerospace, and nuclear sectors.

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.